1. |
中国抗癌协会肝癌专业委员会转化治疗协作组. 肝癌转化治疗中国专家共识(2021版). 中国实用外科杂志, 2021, 41(6): 618-632.
|
2. |
Zhang X, Zhu X, Liu C, et al. The safety and efficacy of transarterial chemoembolization (TACE) + lenvatinib + programmed cell death protein 1 (PD-1) antibody of advanced unresectable hepatocellular carcinoma. J Clin Oncol, 2022, 40(4_suppl): 453.
|
3. |
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版). 中国实用外科杂志, 2020, 40(2): 121-138.
|
4. |
Peng W, Zhang X, Li C, et al. Programmed cell death protein 1 and tyrosine kinase inhibition plus transcatheter arterial chemoembolization of advanced hepatocellular carcinoma. Br J Surg, 2023, 110(7): 746-748.
|
5. |
张晓赟, 李川, 彭伟, 等. 血小板/脾脏体积比预测肝硬化门静脉高压症的严重程度. 腹部外科, 2016, 29(3): 187-192.
|
6. |
Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int, 2015, 35(9): 2155-2166.
|
7. |
Lau WY, Lai EC. Salvage surgery following downstaging of unresectable hepatocellular carcinoma—a strategy to increase resectability. Ann Surg Oncol, 2007, 14(12): 3301-3309.
|
8. |
Tang ZY, Zhou XD, Ma ZC, et al. Downstaging followed by resection plays a role in improving prognosis of unresectable hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int, 2004, 3(4): 495-498.
|
9. |
Zhu XD, Huang C, Shen YH, et al. Hepatectomy after conversion therapy using tyrosine kinase inhibitors plus anti-PD-1 antibody therapy for patients with unresectable hepatocellular carcinoma. Ann Surg Oncol, 2023, 30(5): 2782-2790.
|
10. |
Wang J, Zheng Z, Wu T, et al. Hepatic arterial infusion chemotherapy as a timing strategy for conversion surgery to treat hepatocellular carcinoma: a single-center real-world study. J Hepatocell Carcinoma, 2022, 9: 999-1010.
|
11. |
Shimose S, Iwamoto H, Shirono T, et al. The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Cancer Med, 2023, 12(11): 12325-12335.
|
12. |
Yi Y, Sun BY, Weng JL, et al. Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: a retrospective study. Front Oncol, 2022, 12: 1046584. doi: 10.3389/fonc.2022.1046584.
|
13. |
Guiu B, Chevallier P, Denys A, et al. Simultaneous trans-hepatic portal and hepatic vein embolization before major hepatectomy: the liver venous deprivation technique. Eur Radiol, 2016, 26(12): 4259-4267.
|
14. |
Makuuchi M, Thai BL, Takayasu K, et al. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery, 1990, 107(5): 521-527.
|
15. |
Schnitzbauer AA, Lang SA, Goessmann H, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg, 2012, 255(3): 405-414.
|
16. |
刘畅, 张晓赟, 金谌, 等. 肝静脉系统栓堵术在第二阶段根治性肝癌切除术中的应用. 中国普外基础与临床杂志, 2019, 26(7): 841-846.
|
17. |
Botea F, Barcu A, Verdea C, et al. Regenerative liver surgery—ALPPS and associated techniques. Chirurgia (Bucur), 2021, 116(4): 387-398.
|
18. |
Zhao HT, Cai JQ. Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma. World J Gastroenterol, 2021, 27(47): 8069-8080.
|
19. |
Zhang JL, Zhang XH, Mu H, et al. Surgical conversion for initially unresectable locally advanced hepatocellular carcinoma using a triple combination of angiogenesis inhibitors, anti-PD-1 antibodies, and hepatic arterial infusion chemotherapy: a retrospective study. Front Oncol, 2021, 11: 729764.
|
20. |
Zhu XD, Huang C, Shen YH, et al. Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations. Liver Cancer, 2021, 10(4): 320-329.
|
21. |
He MK, Liang RB, Zhao Y, et al. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma. Ther Adv Med Oncol, 2021, 13: 17588359211002720. doi: 10.1177/17588359211002720.
|
22. |
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版). 中国实用外科杂志, 2022, 42(3): 241-273.
|
23. |
Sparrelid E, Olthof PB, Dasari BVM, et al. Current evidence on posthepatectomy liver failure: comprehensive review. BJS Open, 2022, 6(6): zrac142.
|
24. |
van den Broek MA, Olde Damink SW, Dejong CH, et al. Liver failure after partial hepatic resection: definition, pathophysiology, risk factors and treatment. Liver Int, 2008, 28(6): 767-780.
|
25. |
Hammond JS, Guha IN, Beckingham IJ, et al. Prediction, prevention and management of postresection liver failure. Br J Surg, 2011, 98(9): 1188-1200.
|
26. |
Kong QY, Li C, Wang MD, et al. A web-based prediction model for estimating the probability of post-hepatectomy major complications in patients with hepatocellular carcinoma: a multicenter study from a hepatitis B virus-endemic area. J Gastrointest Surg, 2022, 26(10): 2082-2092.
|